Literature DB >> 33681418

Histomorphometric Effects of 2% Risedronate Gel on Calvarial Bone Defects in Rabbits.

Shabnam Aghayan1, Ahmad Asghari2, Pejman Mortazavi3, Shirin Marzoughi4.   

Abstract

STATEMENT OF THE PROBLEM: Alveolar bone resorption associated with periodontal disease is a common finding and generally irreversible. It impairs mastication and causes esthetic problems for patients. Bisphosphonates are the most commonly used antiresorptive agents for bone diseases.
PURPOSE: Considering the risk of bisphosphonate-related osteonecrosis of the jaw, this study aimed to assess the effect of 2% risedronate gel on calvarial bone defects in rabbits. MATERIALS AND
METHOD: In this animal study, critical-size defects of 8mm were created in the calvaria of 20 New Zealand white rabbits. In group 1 (n=10), 2% risedronate gel was applied into the right side defect while the left side defect remained empty and served as control. In group 2 (n=10), placebo gel was applied into the right side defect, while the left side defect remained empty and served as control. Five rabbits in each group were sacrificed at 1month and the remaining five at 2 month, post-operatively, and tissue samples were collected for histomorphometric analysis. Histomorphometric assessments included bone fill, degree of inflammation, number of osteoblasts, number of osteoclasts, and foreign body reaction at the site. Data were statistically analysed using SPSS version 25 via the Dunn test and Kruskal-Wallis test.
RESULTS: No bone remodeling was noted in any group at 1 month. The risedronate group showed significantly higher bone fill than the other groups after 2 months (p= 0.016). At 2 months, the number of osteoblasts was significantly higher in the risedronate group (p< 0.05). The groups were not significantly different in terms of inflammation score at 1 (p= 0.31) or 2 (p=0.69) months. Foreign body reaction was not observed in any group at any time point. No osteoclast was detected in any group at any time point.
CONCLUSION: Risedronate gel showed superior efficacy with regard to regeneration of rabbit calvarial bone defects compared to the placebo and control groups. Copyright: © Journal of Dentistry.

Entities:  

Keywords:  Bone Loss; Osteoclast; Rabbit; Risedronate

Year:  2021        PMID: 33681418      PMCID: PMC7921771          DOI: 10.30476/DENTJODS.2020.82926.1032

Source DB:  PubMed          Journal:  J Dent (Shiraz)        ISSN: 2345-6418


  15 in total

Review 1.  Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases.

Authors:  O Filleul; E Crompot; S Saussez
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

2.  Effect of locally administered novel biodegradable chitosan based risedronate/zinc-hydroxyapatite intra-pocket dental film on alveolar bone density in rat model of periodontitis.

Authors:  Deepak Kumar Khajuria; Saadath Fathima Zahra; Rema Razdan
Journal:  J Biomater Sci Polym Ed       Date:  2017-11-08       Impact factor: 3.517

3.  Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study.

Authors:  Paolo Vescovi; Giuseppina Campisi; Vittorio Fusco; Giovanni Mergoni; Maddalena Manfredi; Elisabetta Merigo; Luigi Solazzo; Mario Gabriele; Giovanni M Gaeta; Gianfranco Favia; Franco Peluso; Giuseppe Colella
Journal:  Oral Oncol       Date:  2011-02-02       Impact factor: 5.337

4.  Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

Authors:  E van Beek; E Pieterman; L Cohen; C Löwik; S Papapoulos
Journal:  Biochem Biophys Res Commun       Date:  1999-10-14       Impact factor: 3.575

5.  Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial.

Authors:  Anuj Sharma; A R Pradeep
Journal:  J Periodontol       Date:  2011-05-04       Impact factor: 6.993

6.  Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro.

Authors:  M F Moreau; C Guillet; P Massin; S Chevalier; H Gascan; M F Baslé; D Chappard
Journal:  Biochem Pharmacol       Date:  2006-11-03       Impact factor: 5.858

7.  Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.

Authors:  C Dannemann; K W Grätz; M O Riener; R A Zwahlen
Journal:  Bone       Date:  2007-01-22       Impact factor: 4.398

8.  A comparative evaluation of the systemic and local alendronate treatment in synthetic bone graft: a histologic and histomorphometric study in a rat calvarial defect model.

Authors:  Hulya Toker; Hakan Ozdemir; Hatice Ozer; Kaya Eren
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-05-11

9.  Surgical treatment of bisphosphonate-associated osteonecrosis: Prognostic score and long-term results.

Authors:  Waldemar Reich; Udo Bilkenroth; Johannes Schubert; Claudia Wickenhauser; Alexander Walter Eckert
Journal:  J Craniomaxillofac Surg       Date:  2015-08-06       Impact factor: 2.078

10.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

View more
  1 in total

1.  Sustained Release of Risedronate from PLGA Microparticles Embedded in Alginate Hydrogel for Treatment of Bony Lesions

Authors:  Ghazaleh Azari; Shabnam Aghayan; Ehsan Seyedjafari
Journal:  Iran Biomed J       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.